Overview

Terray Therapeutics focuses on discovering and developing small molecule drugs using a combination of experimental techniques and computational methods. The company collects and analyzes a large amount of data, with over two billion unique target-ligand binding measurements, to enhance the drug discovery process through generative AI. This data-driven approach allows for precise predictions of molecular properties using deep learning models. Terray operates a fast design-make-test-analyze cycle, completing each cycle in under a month, which enables the exploration of a wide range of chemical compounds efficiently. While the primary focus is on immunology, Terray collaborates with major pharmaceutical and biotech companies to tackle various therapeutic challenges, creating additional revenue opportunities alongside its own drug discovery projects.

Simplify's Take

What believers are saying

• Terray's partnerships with Gilead and Bristol Myers Squibb enhance its market reach.
• The $120 million Series B funding boosts Terray's research and development capabilities.
• Generative AI trends support Terray's innovative drug discovery approach.

What critics are saying

• Dependence on partnerships may limit Terray's strategic autonomy.
• Rapid AI advancements could render Terray's platform obsolete if not updated.
• Regulatory challenges for AI-driven drug discovery could impact Terray's progress.

What makes Terray Therapeutics unique

• Terray integrates experimentation and computation for efficient small molecule drug discovery.
• The company generates over 150 million new target-ligand measurements monthly.
• Terray's rapid cycle allows exploration of millions of molecules in under a month.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$189.7M

Above

Industry Average

Funded Over

3 Rounds

$120,000,000

Series B

Oct 2024

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.

Series B Funding Comparison

Above Average

Industry standards

Ind Avg. $35M

$4M

$30M

$45M

$65M

$100M

$120M

View all funding stages